Global biopharmaceutical company Almirall has announced that Gianfranco Nazzi will be the company's new CEO and executive director of the Board of Directors effective May 1, 2021.
"I´m very pleased to announce that the Board of Directors have agreed to appoint Gianfranco Nazzi. Nazzi is a trusted leader in the Pharma industry and brings with him a wealth of experience in areas key to the success and growth of Almirall, in the U.S., Europe and Emerging Markets. I am convinced he will bring what is needed to develop Almirall to the next level," said Jorge Gallardo, chairman of the board and president of Almirall.
Mr. Nazzi previously worked for Teva Pharmaceuticals Industries, where he served as executive VP of the International Markets Region and as a member of the Teva Executive Committee. Prior to Teva, Mr. Nazzi held a variety of senior positions at Astra Zeneca, GSK and Eli Lilly in commercial and general management roles based in the UK, Italy, Serbia and the U.S.
"I am really excited to join Almirall and its talented team of professionals. The company's focus on putting patients at the center of all that they do is inspiring and I am sure that I will be able to continue to support them and provide them with novel and value added solutions and treatments to improve their lives. I am committed to this mission and I know that, together with the team, we will achieve great milestones in the near future," said Nazzi.
Nazzi will take over the CEO duties from Mike McClellan, who at the beginning of the year was appointed interim CEO in addition to his role as CFO after the company's former CEO, Peter Guenter, left Almirall to pursue other professional endeavors.
